GNS Healthcare

Using data from the Parkinson's Progression Markers Initiative, GNS Healthcare identifies genetic and molecular markers of rapid motor progression.

Swedish Cancer Institute has enlisted machine-learning technology vendor GNS Healthcare to model patient-specific breast cancer tumor data.

The companies plan to use machine learning and simulation to study disease drivers and identify existing and new therapies, focusing first on cardiovascular disease.

Most recently, Celgene has licensed the GNS platform for internal use and made an undisclosed equity investment in the company.

The firm will use the funding, which comes from both new and existing investors, to develop new cloud-based solutions for precision medicine.

GNS Healthcare and the Multiple Myeloma Research Foundation to use GNS' informatics solutions to explore genomic and clinical data from the CoMMpass study.

Robert Hoyt has joined GenomeQuest's board of directors
Hoyt is currently Eximo's chief operating officer. Prior to that, he was the general manager of Endeca Technologies which sold to Oracle in 2011.

Knome has hired Josh Forsythe as its new vice president of sales and marketing. He joins the company after 10 years at Golden Helix, where held several positions including VP of business development, VP of sales and marketing, and director of marketing.

Increasing investments from venture capital firms in commercial bioinformatics indicates that the perceived value of the market is rising and suggests a level of optimism about the revenue potential of a segment of the life sciences space that historically hasn't been seen as par

GNS Healthcare will use a portion of the proceeds from a recently wrapped $10 million funding round to add support for new types of data to its proprietary analytics platform and to reengineer the system’s software and code so that its analysis is more automated, according to a c

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.